Shop for the production of tablet medicines. File photoTOKYO, May 12. Leading Japanese pharmaceutical companies are reducing their operations in Russia due to difficulties in logistics and financial transactions, the Nikkei newspaper writes. In particular, Daiichi Sankyo Corporation has suspended sales of such drugs such as the anticoagulant Lixiana, the antiplatelet drug Efient and the anti-inflammatory drug Transamin. The publication notes that the company's decision is due to practical difficulties in the supply of drugs, in particular, their transportation. In addition, the company was convinced that there are analogues of these drugs on the Russian market. abroadIn turn, another pharmaceutical company, Eiken Chemical, has suspended the supply of reagents that are used in blood testing for cancer. Earlier, the American pharmaceutical company Eli Lilly announced that it was suspending investments, clinical trials and the import of some of its drugs into Russia. The suspension of deliveries to Russia was also announced by the American company Abbvie, which also owns the Allergan brand, whose Botox drug gave the name to the cosmetic procedure. In April, Russian Prime Minister Mikhail Mishustin reported that due to external pressure and disruption of supply chains, difficulties with the delivery of medicines, the Russian Cabinet of Ministers is taking measures, in particular, launching a special program to support the backbone enterprises of the pharmaceutical and medical industries. will not affect drug supply
